CO2022010592A2 - Métodos de tratamiento de la esplenomegalia - Google Patents

Métodos de tratamiento de la esplenomegalia

Info

Publication number
CO2022010592A2
CO2022010592A2 CONC2022/0010592A CO2022010592A CO2022010592A2 CO 2022010592 A2 CO2022010592 A2 CO 2022010592A2 CO 2022010592 A CO2022010592 A CO 2022010592A CO 2022010592 A2 CO2022010592 A2 CO 2022010592A2
Authority
CO
Colombia
Prior art keywords
splenomegaly
methods
treatment
therapeutic methods
treating
Prior art date
Application number
CONC2022/0010592A
Other languages
English (en)
Inventor
Wayne Philip Rothbaum
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of CO2022010592A2 publication Critical patent/CO2022010592A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describen métodos terapéuticos y composiciones farmacéuticas para tratar la esplenomegalia en un sujeto humano. En ciertas realizaciones, la invención incluye métodos terapéuticos para tratar la esplenomegalia usando un inhibidor de BTK.
CONC2022/0010592A 2020-01-08 2022-07-28 Métodos de tratamiento de la esplenomegalia CO2022010592A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
CO2022010592A2 true CO2022010592A2 (es) 2022-10-31

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0010592A CO2022010592A2 (es) 2020-01-08 2022-07-28 Métodos de tratamiento de la esplenomegalia

Country Status (14)

Country Link
EP (2) EP4000624A1 (es)
JP (1) JP2023509968A (es)
KR (1) KR20220130151A (es)
CN (1) CN114423457A (es)
AU (1) AU2021205484A1 (es)
BR (1) BR112022013646A2 (es)
CA (1) CA3164063A1 (es)
CO (1) CO2022010592A2 (es)
CR (1) CR20220374A (es)
IL (1) IL294582A (es)
JO (1) JOP20220168A1 (es)
MA (1) MA57226B1 (es)
MX (1) MX2022008490A (es)
WO (1) WO2021142257A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
KR20220130151A (ko) * 2020-01-08 2022-09-26 텔리오스 파마, 인크. 비장비대의 치료 방법
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
WO2024041614A1 (en) * 2022-08-25 2024-02-29 Beigene Switzerland Gmbh Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
DK3179991T3 (da) * 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
US9708348B2 (en) * 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2019243223A1 (en) * 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
KR20220130151A (ko) * 2020-01-08 2022-09-26 텔리오스 파마, 인크. 비장비대의 치료 방법

Also Published As

Publication number Publication date
CA3164063A1 (en) 2021-07-15
EP3980069A4 (en) 2022-08-17
MA57226A1 (fr) 2023-02-28
AU2021205484A1 (en) 2022-08-18
CR20220374A (es) 2023-01-25
MX2022008490A (es) 2022-10-13
JOP20220168A1 (ar) 2023-01-30
IL294582A (en) 2022-09-01
CN114423457A (zh) 2022-04-29
MA57226B1 (fr) 2023-06-28
JP2023509968A (ja) 2023-03-10
WO2021142257A1 (en) 2021-07-15
KR20220130151A (ko) 2022-09-26
BR112022013646A2 (pt) 2022-10-04
EP4000624A1 (en) 2022-05-25
EP3980069A1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201892510A2 (ru) Комбинированная терапия для лечения рака
MX2020009773A (es) Terapia de combinacion.
EA202091846A1 (ru) Соединения с активностью, индуцирующей ферроптоз, и способы их применения
MX2020010322A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
CO2020014599A2 (es) Métodos para tratar cáncer
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
CY1125104T1 (el) Συνθεσεις φλαγελλινης entrecoccus για χρηση στη θεραπεια
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
MX2021009051A (es) Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
BR112022015533A2 (pt) Composições e métodos para tratar doenças oculares
MX2021009413A (es) Materiales y métodos para tratar una enfermedad neurodegenerativa.
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
PL423673A1 (pl) Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis
BR112022011228A2 (pt) Formulação farmacêutica líquida, artigo de fabricação, kit e método para tratar uma doença ou distúrbio em um indivíduo